Date:1/29/2008

m cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company's business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company.

Contact:

Financial Media Inquiries

Mona Walsh

212-704-4598

mona.walsh@edelman.com

General Media Inquiries

Kellie Hotz

312-240-2701

kellie.hotz@edelman.com

'/>"/>

SOURCE Cryo-Cell International Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Access Pharmaceuticals Announces $2.7 Million New Equity
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
3. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
4. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
5. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
6. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
7. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
8. Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic
9. Hoya Announces Third Quarter and Nine Month Results for 2007
10. Medefield Announces New Appointments to North American Business Unit
11. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results